Context

  • Client: A small-cap, biotechnology company
  • Product: Biologic molecule for ultra-orphan indication; licensed and launched in US and Japan, applying for a license in Europe
  • Aim: To assess the value of the molecule vs. other ultra-orphans and develop a European pricing strategy

The Challenge

  • No authorised treatments for the indication
  • Potential issues about product wastage and vial splitting
  • Consideration of flat vs. linear vial pricing (and subsequent impact on international reference pricing)

Our Solution

Outcome

  • Identified preliminary ‘named patient sales’ and ‘launch’ price bands, by market, along with expected payer challenges and mitigation plans
  • Estimated multi-year revenue forecast and impact according to different pricing strategies